Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Anaesthesiology|January 7, 2025
Does patient blood management represent good value for money?Adam Irving, Zoe K McQuilten
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 31, 2016
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol DependencePhilippe Laramée, Melissa Bell, Adam Irving, et al.
Transfusion|December 19, 2024
Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for plateletsAdam Irving, Peter Simmonds, William Irving, et al.
Journal of Medical Economics|September 6, 2013
A systematic literature review of utility weights in wet age-related macular degenerationIsobel Pearson, Catherine Rycroft, Adam Irving, et al.
Intensive & Critical Care Nursing|September 10, 2024
A propensity matched cost analysis of medical emergency team calls led by nurse practitioners versus intensive care registrarsSachin Gupta, Ravindranath Tiruvoipati, Mayurathan Balachandran, et al.
Vox Sanguinis|October 14, 2024
Can clinical guidelines reduce variation in transfusion practice? A pre-post study of blood transfusions during cardiac surgeryAdam Irving, Anthony Harris, Dennis Petrie, et al.
The Medical Journal of Australia|July 14, 2024
Multiple myeloma incidence, mortality, and prevalence estimates and projections, Australia, 1982-2043: a statistical modelling studyQingwei Luo, Deanne Jenkin, Marianne F Weber, et al.
Blood Advances|July 31, 2025
Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemiaSara Carrillo De Albornoz, Xin Zhang, Rainier Arnolda, et al.
Critical Care Medicine|April 23, 2019
Fresh Red Cells for Transfusion in Critically Ill Adults: An Economic Evaluation of the Standard Issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) Clinical TrialAdam Irving, Alisa Higgins, Bridget Ady, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
Pageof 2